IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancer
Go back to IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancer| (NASDAQ: IDYA) | Delayed: 38.86 +0.45 (1.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.41 | 52 Week High | $ | |||
| Open | $38.71 | 52 Week Low | $ | |||
| Day High | $39.00 | P/E | N/A | |||
| Day Low | $37.99 | EPS | $ | |||
| Volume | 571,096 | |||||
